A Phase I Study of Ruxolitinib in Combination With Nilotinib in CML Patients With Evidence of Molecular Disease

Trial Profile

A Phase I Study of Ruxolitinib in Combination With Nilotinib in CML Patients With Evidence of Molecular Disease

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Nilotinib
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Aug 2017 Planned End Date changed from 1 Jan 2018 to 1 Mar 2019.
    • 28 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Jan 2018.
    • 06 Dec 2016 Results assessing the maximal tolerated dose (MTD) of ruxolitinib in combination with nilotinib and impact of this combination on BCR-ABL transcript levels, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top